Leone Gina, Rolston Kathy, Spaulding Gail
Amevive, Biogen, Inc, Cambridge, MA, USA.
Dermatol Nurs. 2003 Jun;15(3):216-20, 224-5; quiz 226.
Alefacept (Amevive) is a recombinant, fully human fusion protein that selectively targets memory T cells that have been implicated in the pathogenesis of psoriasis. Alefacept is approved in the United States as a treatment for chronic plaque psoriasis. Alefacept is unique among treatments for moderate to severe psoriasis because of its selective therapeutic action, favorable safety profile, and ability to induce lengthy disease remissions.
阿法赛特（Amevive）是一种重组的全人源融合蛋白，它选择性地靶向参与银屑病发病机制的记忆T细胞。阿法赛特在美国被批准用于治疗慢性斑块状银屑病。阿法赛特在中重度银屑病治疗中独具特色，因其具有选择性治疗作用、良好的安全性以及诱导疾病长期缓解的能力。
